Research Article: Tetra­kis{2-[2-(2,6-dichloro­anilino)phen­yl]ethano­ato-κ2O:O′}bis­[(dimethyl sulfoxide-κO)copper(II)](Cu—Cu): a binuclear CuII complex with the non-steroidal anti-inflammatory drug diclofenac

Date Published: April 01, 2012

Publisher: International Union of Crystallography

Author(s): Stéphanie Sayen, Emmanuel Guillon.


The title compound, [Cu2(C14H10Cl2NO2)4(C2H6OS)2], comprises a CuII2 core that is quadruply bridged by four carboxyl­ate ligands with the dimethyl sulfoxide ligands binding along the Cu⋯Cu axis. The four carboxyl­ate ligands bind in a bidentate syn–syn bridging mode. Mol­ecules reside on crystallographic inversion centres bis­ecting the mid-point of the Cu⋯Cu axis. There are no inter­molecular inter­actions of note.

Partial Text

CuII complexes of non-steroidal anti-inflammatory drugs (NSAIDs) show enhanced anti-inflammatory activity and reduced gastrointestinal toxicity compared with their uncomplexed parent drug, see: Weder et al. (2002 ▶). The structure of the Cu–NSAID is likely to be an important factor for its biological activity. For example, the anti-tumor activity of the monomeric CuII complex of aspirin ([Cu(Asp)2(py)2]) is reportedly more effective than the dimeric [Cu2(Asp)4] complex, see: Oberley & Buettner (1979 ▶). It has been shown that dinuclear Cu–NSAID complexes exhibit similar bio­logical activity to mononuclear complexes, but with higher stability (Dimiza et al., 2011 ▶), making them relevant compounds in the treatment of tumor cell lines (Theodorou et al., 1999 ▶). For mono- and binuclear CuII complexes of diclofenac, see: Sayen et al. (2012 ▶) for [Cu(diclofenac)2(H2O)2]·2H2O and Kovala-Demertzi et al. (1997 ▶) for [Cu2(diclofenac)4(DMF)2].